On October 19, 2009, Aptiom, Inc., an indirect wholly-owned subsidiary of Dainippon Sumitomo Pharma Co., Ltd. completed its subsequent tender offer for Sepracor Inc. (“SEPR”) Common Shares. The merger was subsequently consummated on October 20, 2009. As a result, each existing SEPR Common Share will be converted into the right to receive $23.00 net cash per share.
This action will be coordinated with the Options Clearing Corporation.
Register for regular updates here and manage your email preferences.